Brainstorm Cell Therapeutics (BCLI)

4.30 -0.11 (2.49%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/15/18 *Est.)

Latest Headlines

Form S-3 BRAINSTORM CELL THERAPEU June 8, 2018 11:41 AM - SEC Filing Form 424B3 BRAINSTORM CELL THERAPEU June 7, 2018 8:07 AM - SEC Filing Form 8-K BRAINSTORM CELL THERAPEU For: Jun 06 June 7, 2018 8:01 AM - SEC Filing BrainStorm Announces Exercise of Warrants Resulting in Cash Proceeds of ~$12.3 Million at $5 Share June 7, 2018 8:00 AM - PR NewsWire BrainStorm to Host Call Following President Trump's Citing of Company's ALS Treatment During "Right-to-Try" Bill Signing June 1, 2018 7:50 AM - PR NewsWire BrainStorm Cell Therapeutics to Provide Corporate Update at the BIO International Convention May 30, 2018 1:25 AM - PR NewsWire Brainstorm Cell Therapeutics (BCLI) Releases Statement on 'Right to Try' Legislation May 25, 2018 9:20 AM - StreetInsider BrainStorm Cell Therapeutics Issues Statement on "Right to Try" Legislation May 25, 2018 9:19 AM - PR NewsWire UPDATE: H.C. Wainwright Starts Brainstorm Cell Therapeutics (BCLI) at Buy May 15, 2018 7:08 AM - StreetInsider Brainstorm Cell Therapeutics (BCLI) Reports Q1 Loss of $0.12/Share May 14, 2018 8:06 AM - StreetInsider Form 10-Q BRAINSTORM CELL THERAPEU For: Mar 31 May 14, 2018 8:03 AM - SEC Filing BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical Highlights May 14, 2018 8:00 AM - PR NewsWire BrainStorm CEO to Present at World Advanced Therapy and Regenerative Medicine Congress in London May 9, 2018 1:00 AM - PR NewsWire Brainstorm to Announce First Quarter Financial Results and Provide Corporate Update on Monday, May 14 May 8, 2018 7:12 AM - PR NewsWire BrainStorm Cell Therapeutics to Participate in Movement Disorder Panel at the Neurotech Investing and Partnering Conference May 1, 2018 9:01 AM - PR NewsWire BrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New York April 11, 2018 1:01 AM - PR NewsWire Brainstorm Cell Therapeutics (BCLI) Announces Phase 3 Trial of NurOwn in ALS Now Open to Canadian Patients March 28, 2018 6:00 AM - StreetInsider BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients March 28, 2018 5:54 AM - PR NewsWire Form 4 BRAINSTORM CELL THERAPEU For: Mar 06 Filed by: Kern Ralph Dr. March 26, 2018 4:50 PM - SEC Filing Form 4 BRAINSTORM CELL THERAPEU For: Mar 26 Filed by: Araya Arturo March 26, 2018 4:47 PM - SEC Filing BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board March 21, 2018 8:00 AM - PR NewsWire Full Article List